2026 Leads Networking 
European Pharmaceutical Review
NOVEMBER 15, 2023
Sandoz] has the only major remaining vertically-integrated production network for penicillins in Europe” Penicillins are the leading category of antibiotics worldwide, Sandoz highlighted. Launch of these new facilities help to ensure sustainable access to quality antibiotics and spearhead development of biosimilars, Sandoz noted.
Pharmaceutical Technology
MARCH 10, 2023
It represents one of the largest-ever global private-sector investments in the country and strengthens the company’s Europe-wide production network. At Sandoz, we are determined to continue leading the way in driving access to these critical medicines.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Clarivate
MAY 14, 2024
While initially developed to help regulate blood sugar levels, they have also been found to promote appetite suppression, leading to weight loss in patients. What’s leading to the boom in development of semaglutide biosimilars? Per recent Clarivate estimates, the therapeutic market for these drugs is valued at approximately $1.7
Clarivate
AUGUST 7, 2024
Express Scripts ClearNetwork (effective from early 2024) Cost-plus pricing model; includes ESI’s 65,000-plus site retail pharmacy network; prescription pricing is based on the lowest of three benchmarks: NADAC, WAC or PAC; Pharmacies receive a flat dispensing fee plus up to 15% markup.
Clarivate
APRIL 24, 2023
Oak Street has 169 locations across 21 states and expects to nearly double its size to 300 centers by 2026. Lines are blurring between payers and providers More and more, large integrated delivery networks and national payers are battling each other for greater control over patient costs and outcomes.
Clarivate
SEPTEMBER 5, 2024
Starting in 2026, the first ten self-administered Part D drugs in the law’s cross hairs will receive price cuts of 38%-79%. With the passage of the Inflation Reduction Act (IRA), the United States government gained the ability to directly negotiate drug prices with manufacturers.
pharmaphorum
DECEMBER 14, 2022
Angelini Ventures will lend its network and knowledge of the life sciences industry to “strengthen the bridge between the excellence of Italian academic research and the development of drug discovery programmes in order to identify new treatment options,” said Angelini Industries CEO Professor Sergio Marullo di Condojanni in a statement. “We
Expert insights. Personalized for you.
93 
Let's personalize your content